1094 related articles for article (PubMed ID: 21752599)
1. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
Aharoni R; Eilam R; Stock A; Vainshtein A; Shezen E; Gal H; Friedman N; Arnon R
J Neuroimmunol; 2010 Aug; 225(1-2):100-11. PubMed ID: 20554028
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.
Aharoni R; Sasson E; Blumenfeld-Katzir T; Eilam R; Sela M; Assaf Y; Arnon R
Exp Neurol; 2013 Feb; 240():130-44. PubMed ID: 23153580
[TBL] [Abstract][Full Text] [Related]
4. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.
Papadopoulos D; Pham-Dinh D; Reynolds R
Exp Neurol; 2006 Feb; 197(2):373-85. PubMed ID: 16337942
[TBL] [Abstract][Full Text] [Related]
5. Early axonal damage and progressive myelin pathology define the kinetics of CNS histopathology in a mouse model of multiple sclerosis.
Recks MS; Stormanns ER; Bader J; Arnhold S; Addicks K; Kuerten S
Clin Immunol; 2013 Oct; 149(1):32-45. PubMed ID: 23899992
[TBL] [Abstract][Full Text] [Related]
6. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
7. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
Black JA; Liu S; Hains BC; Saab CY; Waxman SG
Brain; 2006 Dec; 129(Pt 12):3196-208. PubMed ID: 16931536
[TBL] [Abstract][Full Text] [Related]
8. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
[TBL] [Abstract][Full Text] [Related]
9. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.
Zhang GX; Yu S; Gran B; Li J; Calida D; Ventura E; Chen X; Rostami A
J Neuroimmunol; 2004 Mar; 148(1-2):1-10. PubMed ID: 14975581
[TBL] [Abstract][Full Text] [Related]
10. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes.
Kerlero de Rosbo N; Mendel I; Ben-Nun A
Eur J Immunol; 1995 Apr; 25(4):985-93. PubMed ID: 7737302
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
Liblau R
J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
13. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
15. Differential patterns of spinal cord pathology induced by MP4, MOG peptide 35-55, and PLP peptide 178-191 in C57BL/6 mice.
Kuerten S; Gruppe TL; Laurentius LM; Kirch C; Tary-Lehmann M; Lehmann PV; Addicks K
APMIS; 2011 Jun; 119(6):336-46. PubMed ID: 21569091
[TBL] [Abstract][Full Text] [Related]
16. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
17. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.
Chan J; Ban EJ; Chun KH; Wang S; McQualter J; Bernard C; Toh BH; Alderuccio F
Autoimmunity; 2008 Aug; 41(5):405-13. PubMed ID: 18568646
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
Racke MK; Lovett-Racke AE
J Immunol; 2011 Feb; 186(4):1887-90. PubMed ID: 21289312
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings in rats with experimental allergic encephalomyelitis.
Dong M; Liu R; Guo L; Li C; Tan G
APMIS; 2008 Nov; 116(11):972-84. PubMed ID: 19132994
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
Aharoni R
Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
